SEC Filing Summary
Entity note: The filing is for Novus Therapeutics, Inc. (Nasdaq: NVUS), not Eledon Pharmaceuticals, Inc. It is a Form 10-Q for the quarter ended June 30, 2020, filed August 13, 2020. Financial amounts below are in U.S. dollars unless stated otherwise; statement amounts are in thousands.
Business context and reporting period
Novus is a clinical-stage specialty pharmaceutical company developing treatments for ear, nose and throat disorders. Its lead candidate, OP0201, is a nasal aerosol being developed for otitis media. The foam-based product programs were on hold, and the company was reviewing development options and strategic alternatives.
Financial performance and position
| Metric | Q2 2020 | Q2 2019 | Six months 2020 | Six months 2019 |
|---|---|---|---|---|
| Revenue | No product revenue | No product revenue | No product revenue | No product revenue |
| Research and development expense | $0.832 million | $2.297 million | $2.480 million | $5.286 million |
| General and administrative expense | $1.269 million | $1.792 million | $2.999 million | $3.678 million |
| Restructuring expense | $0.490 million | — | $0.490 million | — |
| Net loss | $2.586 million | $4.093 million | $10.763 million | $8.974 million |
| Net loss per share | $0.15 | $0.35 | $0.63 | $0.85 |
| Cash used in operating activities | — | $5.218 million | $8.945 million |
At June 30, 2020, cash was $8.764 million, working capital was $8.7 million, total assets were $10.501 million, total liabilities were $1.145 million and accumulated deficit was $68.345 million. The filing reports no outstanding debt or committed credit facilities. Cash declined by $27,000 during the first half; warrant exercises provided $5.191 million in financing cash flow. The company stated it did not have sufficient cash to fund operations for 12 months from filing and disclosed substantial doubt about its ability to continue as a going concern. No clear quantified runway estimate is provided.
Material changes versus prior comparable periods
- Q2 operating expenses fell 37% year over year, mainly as OP0201 clinical and formulation-development costs declined; net loss narrowed 37% to $2.586 million.
- First-half operating expenses fell 33%, but net loss increased 20% to $10.763 million, primarily due to a $4.829 million non-cash warrant inducement expense recorded in 2020.
- First-half operating cash use improved from $8.945 million to $5.218 million, while cash financing proceeds fell from $9.676 million in 2019 to $5.191 million in 2020.
- Common shares outstanding increased from 12.967 million at December 31, 2019 to 19.380 million at June 30, 2020, mainly from warrant exercises and conversion of preferred stock.
Outlook, risks and unusual items
- OP0201’s Phase 2a trial in infants and children did not meet its primary efficacy endpoints. The company reported a favorable trend in resolution of middle-ear effusion: 56% of OP0201 patients versus 38% of placebo patients (p=0.07).
- In June, Novus completed a workforce reduction and accrued $490,000 in separation and post-employment benefit costs, expected to be paid within nine months. It also limited R&D activity while reviewing strategic and development alternatives, including financing, sale, merger, asset sale, licensing or other transactions; no outcome or timing was assured.
- The board-approved reverse-split authorization allows a 1-for-10 to 1-for-30 split. The company cited October 19, 2020 as the extended deadline to regain Nasdaq’s $1 minimum bid-price compliance; a split was expected if needed, but compliance was not assured.
- COVID-19 created operational and financing-market uncertainty. Management said the pandemic had not materially affected OP0201 study C-006, but further disruption could delay development or constrain access to capital.
- A shareholder securities lawsuit relating to predecessor Tokai’s galeterone clinical-trial disclosures remained unresolved. The company said it could not estimate a possible loss range and intended to defend the case.
Important facts for investors to verify
- Confirm the filing entity and ticker: this report is Novus Therapeutics (NVUS), not Eledon Pharmaceuticals.
- Review the complete Phase 2a results and whether management or a strategic partner intends to advance OP0201 despite failure on the primary endpoints.
- Check subsequent financing, strategic-review developments and cash runway; the filing states substantial doubt about going concern and provides no assured funding plan.
- Verify Nasdaq bid-price compliance and whether the authorized reverse stock split was implemented.
- Assess potential dilution from outstanding warrants, Series X preferred shares and any future equity financing; 7,415,591 warrants were exercisable at June 30, 2020.
- Track developments in the Tokai securities litigation and any resulting financial exposure.